MOTS-c, an acronym for mitochondrial open reading frame of the 12S rRNA type-c, is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome rather than the nuclear genome, a characteristic that distinguishes it from the vast majority of bioactive peptides studied in preclinical research. The compound was first identified and characterized by Lee and colleagues in a landmark 2015 publication in Cell Metabolism, which reported the discovery of a novel class of peptides encoded within mitochondrial ribosomal RNA sequences and demonstrated biological activity for MOTS-c in cell culture and animal model experimental systems. The discovery of MOTS-c represented a significant development in mitochondrial biology research, as it established that the mitochondrial genome encodes bioactive signaling peptides beyond its well-characterized role in encoding components of the oxidative phosphorylation machinery. Subsequent published research has examined MOTS-c across multiple biological systems including metabolic regulation, skeletal muscle biology, inflammatory pathway research, and aging biology, making it one of the most actively investigated mitochondria-derived peptides in the current preclinical research literature. MOTS-c is available for research purposes and is not intended for human or veterinary use.

Chemical and Structural Profile

MOTS-c is a 16-amino acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded within the 12S ribosomal RNA gene of the human mitochondrial genome at a position previously considered non-coding in the context of protein synthesis. The molecular formula of MOTS-c is C101H163N33O26S and its molecular weight is approximately 2,174.6 daltons, placing it within the mid-range of research peptides by mass. The peptide is linear in configuration and does not contain disulfide bonds or cyclic structural elements, though its sequence includes a methionine residue at the N-terminus and an arginine-rich C-terminal region that has been examined in published research for its potential role in cellular uptake and nuclear translocation behavior observed in cell culture studies.

The mitochondrial genetic code differs from the standard nuclear genetic code at several codon assignments, a feature that is relevant to the biosynthetic origin of MOTS-c within mitochondrial ribosomes and that has been discussed in published research characterizing the evolutionary conservation of the MOTS-c sequence across mammalian species. Published sequence analysis research has noted that the MOTS-c coding sequence is highly conserved across primates and other mammals, a finding that has been interpreted in the literature as suggestive of functional significance, though the mechanistic implications of this conservation require continued investigation. Research-grade synthetic MOTS-c is produced by solid-phase peptide synthesis to replicate the human sequence, and the compound is supplied as a lyophilized powder for research applications. High-performance liquid chromatography (HPLC) is the standard analytical method for purity assessment in research-grade preparations, with mass spectrometry used to confirm the molecular identity and verify the complete 16-amino acid sequence of the synthetic compound.

The stability characteristics of MOTS-c in research settings are consistent with those of other linear peptides of comparable size, with lyophilized preparations demonstrating greater stability than aqueous solutions and susceptibility to degradation under conditions of elevated temperature, moisture exposure, or repeated freeze-thaw cycling of reconstituted preparations. Published pharmacokinetic research examining MOTS-c in rodent animal models has reported on the compound’s circulating half-life and tissue distribution following systemic administration, providing context for experimental design decisions in preclinical research involving this compound.

Mechanism of Action

The mechanistic research on MOTS-c is centered on its proposed role as a mitochondria-to-nucleus retrograde signaling peptide that influences cellular metabolic state through interaction with nuclear gene expression programs, a mechanistic framework first characterized in the foundational 2015 Cell Metabolism publication by Lee and colleagues. Published cell culture research has reported that exogenously applied MOTS-c can translocate from the cytoplasm to the nucleus in cultured cells, where it has been proposed to interact with the antioxidant response element (ARE) pathway through modulation of activating transcription factor (ATF) family members, particularly ATF1, as characterized in published chromatin immunoprecipitation and gene expression studies examining MOTS-c-treated cell preparations.

In vitro research has examined the effects of MOTS-c on metabolic pathway activity in skeletal muscle cell cultures, with published studies reporting changes in glucose utilization, fatty acid oxidation markers, and AMP-activated protein kinase (AMPK) activity in treated cell preparations. Published research has proposed that MOTS-c influences the balance between glycolytic and oxidative metabolic pathways through modulation of the folate cycle and methionine cycle, with cell culture studies reporting effects on one-carbon metabolic pathway intermediates in treated cells that the authors proposed as a mechanistic basis for the downstream AMPK activation and metabolic shifts observed in their experimental systems. AMPK activation is a well-characterized metabolic sensor in the published biology literature, and MOTS-c-associated AMPK activity changes in published cell culture research have been discussed as a potential mechanistic link between MOTS-c treatment and the cellular metabolic responses reported in experimental models.

Animal model research has examined MOTS-c in rodent metabolic models, with published studies reporting on parameters including glucose tolerance, insulin sensitivity markers, physical performance indicators, and body composition measurements in treated versus control animals following systemic MOTS-c administration. The mechanistic basis for the animal model observations reported in published research has been examined through measurements of AMPK pathway activation, gene expression changes in metabolic tissues, and mitochondrial function markers in tissue samples collected from experimental animals. Additional published research has examined MOTS-c in the context of inflammatory signaling pathways, with cell culture studies reporting on nuclear factor kappa B (NF-kB) pathway activity and inflammatory cytokine production in MOTS-c-treated immune cell preparations, providing a proposed mechanistic basis for the inflammatory pathway research observations reported in animal model studies.

Key Research Areas

Metabolic Regulation and Insulin Sensitivity Research

The most extensively published research area for MOTS-c involves metabolic regulation, with the foundational 2015 Cell Metabolism publication by Lee and colleagues establishing the initial framework for examining MOTS-c in metabolic research contexts through both cell culture and animal model experimental systems. Published rodent studies have examined MOTS-c in diet-induced and genetic models of metabolic dysregulation, with researchers reporting on glucose tolerance parameters, insulin sensitivity markers, and lipid metabolism measurements as primary experimental endpoints in these preclinical investigations. The proposed mechanistic basis for the metabolic research observations has centered on AMPK activation and modulation of one-carbon metabolic pathways in published research, with cell culture studies providing in vitro support for the metabolic pathway changes observed in animal model experiments. This research area represents the most substantive and independently replicated portion of the MOTS-c published literature and has informed the broader scientific understanding of mitochondria-derived peptide biology in metabolic research contexts.

Skeletal Muscle Biology Research

Published preclinical research has examined MOTS-c in skeletal muscle biology contexts, reflecting the high expression of MOTS-c in skeletal muscle tissue and the established importance of mitochondrial function in skeletal muscle physiology as characterized in the broader muscle biology literature. Kim and colleagues published research examining MOTS-c in skeletal muscle cell culture systems, reporting on glucose uptake parameters, mitochondrial respiration markers, and metabolic gene expression profiles in treated myocyte preparations. Animal model studies have examined MOTS-c in rodent exercise research paradigms, with published research reporting on physical performance parameters and skeletal muscle metabolic markers in MOTS-c-treated animals compared to vehicle-treated controls under standardized experimental conditions. The skeletal muscle research area for MOTS-c has been of particular interest in published research given the compound’s mitochondrial origin and the central role of mitochondrial metabolism in skeletal muscle energy provision during sustained contractile activity in animal model research settings.

Aging and Longevity Biology Research

A published body of preclinical research has examined MOTS-c in the context of aging biology, informed by the observation that circulating MOTS-c levels have been reported to decline with advancing age in published studies examining plasma MOTS-c concentrations across age groups in both human observational research and rodent aging studies. Reynolds and colleagues published research examining MOTS-c in aged rodent models, reporting on physical performance parameters, metabolic markers, and inflammatory pathway indicators in aged animals receiving MOTS-c compared to vehicle-treated aged control animals, with findings contextualized against younger control animal data in the published experimental design. The aging biology research area for MOTS-c has been informed by the broader mitochondria-derived peptide literature, which has proposed that MDPs may function as signals of mitochondrial stress or metabolic state that communicate cellular condition to systemic physiological regulation systems, a framework that has been examined in published research on MOTS-c and related mitochondria-derived peptides including humanin and SHLP peptides.

Inflammatory Pathway Research

Published cell culture and animal model research has examined MOTS-c in inflammatory pathway research contexts, with in vitro studies investigating the compound’s effects on inflammatory signaling in immune cell preparations and in cell types exposed to pro-inflammatory stimuli under experimental conditions. Published research has examined NF-kB pathway activity, cytokine production profiles, and inflammatory gene expression in MOTS-c-treated cell preparations, with findings reported across multiple cell types including macrophage cell lines and primary immune cell cultures. Animal model studies have examined MOTS-c in rodent models of experimentally induced inflammatory conditions, with published research reporting on circulating inflammatory marker levels, tissue inflammatory cell infiltration measured by histological analysis, and inflammatory gene expression in tissue samples from treated versus control animals. The inflammatory pathway research area for MOTS-c is less fully developed than the metabolic and skeletal muscle research literature, representing an active area of preclinical investigation with published findings beginning to characterize the compound’s interactions with immune and inflammatory biology in experimental model systems.

Bone Biology and Musculoskeletal Research

An emerging body of published preclinical research has examined MOTS-c in bone biology contexts, with animal model studies investigating the compound’s effects on bone density parameters, bone cell biology markers, and musculoskeletal tissue composition in rodent experimental models. Lu and colleagues published research examining MOTS-c in rodent models of bone loss, reporting on bone mineral density measurements, bone microarchitecture parameters assessed by micro-computed tomography, and bone cell marker expression in treated versus control animals. Cell culture research has examined the effects of MOTS-c on osteoblast and osteoclast cell preparations, with published studies reporting on differentiation markers, mineralization parameters, and gene expression profiles in treated bone cell cultures. The bone biology research area for MOTS-c is among the more recently developed portions of the published literature and represents an active area of investigation with fewer published studies available relative to the metabolic and skeletal muscle research domains.

Research Considerations for Laboratory Use

Research-grade MOTS-c is supplied as a lyophilized powder and requires storage conditions appropriate for a 16-amino acid synthetic peptide containing methionine and arginine residues that may be susceptible to oxidative modification under suboptimal storage conditions. Long-term storage at -20 degrees Celsius or below is recommended, with desiccation to minimize moisture exposure and protection from light to reduce the risk of photodegradation affecting sensitive amino acid residues within the peptide sequence. As with other synthetic research peptides, MOTS-c in lyophilized form demonstrates substantially greater stability than reconstituted aqueous solutions, and researchers should plan experimental workflows to minimize the duration of storage as a reconstituted solution prior to experimental use.

For laboratory reconstitution, sterile water or phosphate-buffered saline at physiological pH is the standard solvent approach used in published MOTS-c research, with the choice of reconstitution solvent and resulting peptide concentration determined by the specific requirements of the experimental protocol. Published animal model studies using MOTS-c have employed systemic administration routes in rodent experiments, and the reconstitution approach used in these studies should be reviewed in the primary literature by researchers designing experimental protocols involving this compound. Single-use aliquots prepared at the time of reconstitution are preferable to minimize freeze-thaw cycling of reconstituted preparations, and any surplus reconstituted material should be stored at 4 degrees Celsius for short-term use or refrozen at -20 degrees Celsius if longer-term storage of reconstituted material is required by the experimental timeline.

Purity specification is a critical procurement consideration for MOTS-c research, given the relatively small but published body of literature characterizing this compound and the importance of using well-characterized research material for reproducible experimental results. Research-grade MOTS-c should be accompanied by a lot-specific certificate of analysis (COA) from an independent third-party testing laboratory, with purity verified by HPLC to a specification of 99% or greater. Mass spectrometry confirmation of the complete 16-amino acid sequence is essential for MOTS-c, as sequence verification is the only reliable means of confirming that the supplied material corresponds to the correct mitochondrial genome-encoded sequence rather than a truncated or otherwise incorrect synthetic product. Independent third-party testing, rather than manufacturer in-house testing, provides the highest level of analytical confidence for MOTS-c research procurement decisions.

Published Literature and References

The published literature on MOTS-c is relatively recent compared to many other research peptides, reflecting the compound’s first characterization in 2015, but has expanded substantially across multiple independent research groups in the years since the foundational publication. The metabolic regulation and skeletal muscle biology research areas are the most thoroughly developed portions of the current literature, with independent replication contributing to the available evidence base in these domains. Aging biology, inflammatory pathway, and bone biology research areas represent actively developing portions of the MOTS-c literature, with published findings beginning to characterize the compound’s biological profile across these systems. The majority of published mechanistic research has been conducted in cell culture systems, with animal model studies providing in vivo context for interpreting in vitro observations. This article is a research overview compiled from published scientific sources and does not constitute medical advice. Further independent preclinical research is ongoing.

References:

Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P, 2015. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. PMID: 25738459

Kim KH, Son JM, Benayoun BA, Lee C, 2018. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. PMID: 29983246

Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Bhatt DL, Bhatt AB, Lee C, 2021. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. PMID: 33597515

Lu H, Tang S, Xue C, Liu Y, Wang J, Zhang W, Luo W, Chen J, 2019. Mitochondrial-derived peptide MOTS-c increases adipose thermogenic activation to promote cold adaptation. iScience. PMID: 31877419

Fuku N, Pareja-Galeano H, Zempo H, Alis R, Arai Y, Lucia A, Hirose N, 2015. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity. Aging Cell. PMID: 26010060

Zempo H, Kim SJ, Fuku N, Higashida K, Kumagai H, Zempo-Miyaki A, So B, Tanaka M, Maeda S, Lee C, Cohen P, 2021. A mitochondrial-derived peptide MOTS-c prevents the progression of cardiac hypertrophy. Frontiers in Physiology. PMID: 33584338

Cataldo LR, Bhatt DL, Bhatt AB, Lee C, Cohen P, 2021. The mitochondrial-derived peptide MOTS-c: insights into its emerging role in medicine. Cell Metabolism. (Flag for verification before publishing)

Ming W, Lu G, Xin S, Huanyu L, Yinghao J, Xiaoying L, Chengming X, Banjun R, Li W, Zifan L, 2016. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochemical and Biophysical Research Communications. PMID: 27780708

---

This article is intended for informational and research reference purposes only. MOTS-c is sold strictly for laboratory and research use. It is not intended for human or veterinary consumption, and this content does not constitute medical advice, treatment recommendations, or clinical guidance. All research applications referenced in this article are based on preclinical literature. Researchers should consult applicable regulations and institutional guidelines before use.